title: Cholecystokinin modulates the aversive component of morphine withdrawal syndrome in rats.
abstract: The conditioned place aversion paradigm was used to investigate the role of cholecystokinin in the aversive/dysphoric component of morphine abstinence. Several cholecystokinin ligands were chronically administered during the development of morphine dependence: the CCKA antagonist devazepide, the CCKB antagonists PD-134,308 and L-365,260, and the CCKB agonist BC 264. The CCK-B antagonists L-365,260 and PD-134,308 decreased and completely blocked (respectively) the place aversion induced by naloxone in morphine dependent animals whereas BC 264 and devazepide were inactive in this model. No effect was observed in non-dependent animals after chronic administration of these CCK-ligands. These results show a distinct role for CCK receptors in the regulation of the motivational component of morphine abstinence, probably related to their differential effects in the regulation of limbic dopaminergic neurons.
authors.affiliation: Département de Pharmacochimie Moléculaire et Structurale INSERM U266-CNRS URA D 1500, UFR des Sciences Pharmaceutiques et Biologiques, Paris, France.
authors.forename: O
authors.initials: O
authors.lastname: Valverde
authors.forename: B P
authors.initials: BP
authors.lastname: Roques
mesh_terms: D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology; D001362:Avoidance Learning / Q000187:drug effects* / Q000502:physiology; D001570:Benzodiazepinones / Q000494:pharmacology; D002766:Cholecystokinin / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D003214:Conditioning, Classical / Q000187:drug effects / Q000502:physiology; D020109:Devazepide; D007211:Indoles / Q000494:pharmacology; D008297:Male; D008536:Meglumine / Q000031:analogs & derivatives / Q000494:pharmacology; D009021:Morphine Dependence / Q000503:physiopathology*; D010446:Peptide Fragments / Q000494:pharmacology; D010671:Phenylurea Compounds; D051381:Rats; D017208:Rats, Wistar; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology*
chemical_list: D014151:Anti-Anxiety Agents; C084553:BC 264; D001570:Benzodiazepinones; D007211:Indoles; D010446:Peptide Fragments; D010671:Phenylurea Compounds; C065599:PD 134308; C058121:L 365260; D008536:Meglumine; D002766:Cholecystokinin; D020109:Devazepide